The history of Sildenafil presents a complex case for observers in the medicinal sector. While initially a tremendous success, producing vast sums, the intellectual property end and the subsequent arrival of off-brand alternatives have significantly affected earnings. This poses questions about the long-term sustainability of similar medication dev